Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group

Haematologica. 2015 Jan;100(1):e10-3. doi: 10.3324/haematol.2014.112151. Epub 2014 Oct 10.

Authors

Mariella D'Angiò¹, Maria G Valsecchi², Anna M Testi³, Valentino Conter⁴, Vittorio Nunes¹, Rosanna Parasole⁵, Antonella Colombini⁴, Nicola Santoro⁶, Stefania Varotto⁷, Maurizio Caniglia⁸, Daniela Silvestri⁹, Caterina Consarino¹⁰, Laura Levati¹¹, Elisa Magrin⁷, Franco Locatelli¹², Giuseppe Basso⁷, Robin Foà¹, Andrea Biondi⁴, Gianni Cazzaniga¹¹

Affiliations

¹ Department of Cellular Biotechnologies and Hematology, University Sapienza, Roma.
² Center of Biostatistics for Clinical Epidemiology, Department of Health Sciences, University of Milano-Bicocca, Milano.
³ Department of Cellular Biotechnologies and Hematology, University Sapienza, Roma [email protected].
⁴ Department of Pediatrics, University of Milano-Bicocca, Ospedale S. Gerardo / Fondazione MBBM, Monza.
⁵ Department of Pediatric Hemato-Oncology, Ospedale Pausilipon, Napoli.
⁶ Department of Pediatric Hemato-Oncology, University of Bari.
⁷ Department of Woman and Child Health, Hemato-Oncology Division, University of Padova, Azienda Ospedale Padova.
⁸ Department of Pediatric Hemato-Oncology, Ospedale S.M. della Misericordia, Perugia.
⁹ Center of Biostatistics for Clinical Epidemiology, Department of Health Sciences, University of Milano-Bicocca, Milano Department of Pediatrics, University of Milano-Bicocca, Ospedale S. Gerardo / Fondazione MBBM, Monza.
¹⁰ Department of Pediatric Hemato-Oncology, Ospedale Pugliese-Ciaccio, Catanzaro.
¹¹ Centro Ricerca Tettamanti, Department of Pediatrics, Department of Health Sciences, University of Milano-Bicocca, Ospedale S. Gerardo / Fondazione MBBM, Monza.
¹² Department of Pediatric Hemato-Oncology, IRCCS Ospedale Bambino Gesù, Roma.

No abstract available

Keywords: SIL/TAL1; acute lymphoblastic leukemia; children and adolescents.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Basic Helix-Loop-Helix Transcription Factors / genetics
Basic Helix-Loop-Helix Transcription Factors / metabolism*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism*
Child
Child, Preschool
Cohort Studies
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Immunophenotyping
Infant
Intracellular Signaling Peptides and Proteins / genetics
Intracellular Signaling Peptides and Proteins / metabolism*
Male
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / genetics
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / pathology*
Neoplasm Staging
Oncogene Proteins, Fusion / genetics
Patient Outcome Assessment
Polymerase Chain Reaction
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / mortality
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Prognosis
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins / metabolism*
Survival Rate
T-Cell Acute Lymphocytic Leukemia Protein 1

Substances

Basic Helix-Loop-Helix Transcription Factors
Biomarkers, Tumor
Intracellular Signaling Peptides and Proteins
Oncogene Proteins, Fusion
Proto-Oncogene Proteins
SIL-TAL1 fusion protein, human
STIL protein, human
T-Cell Acute Lymphocytic Leukemia Protein 1
TAL1 protein, human